MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term ...

WINNIPEG, Manitoba, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (KNE:CA) (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the Company will be showcasing its ...

A webcast replay of the discussion will be available from the Investors section of the company’s website at www.iobiotech.com for 30 days. A webcast replay of the discussion will be available from the ...

Returning for its fourth year, Bisnow’s International Life Sciences & Biotech Conference returns to San Diego in 2026. As the global life sciences industry continues to drive innovation, this two-day ...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 27, 2025, following ...

Edesa Biotech (EDSA) has released an update. Edesa Biotech, a clinical-stage biopharmaceutical company, is set to participate in multiple international conferences, highlighting its focus on ...

Krystal Biotech, Inc. announced that it will present multiple research programs focused on lung, eye, and skin conditions at several scientific conferences in May and June 2025. The presentations ...

The biotech industry’s largest annual conclave comes to Boston next week, and it’s a stressful time for those in the business of developing new drugs and medical treatments. Companies are declaring ...

Company management will be participating in one-on-one investor meetings at the conferences. To schedule a meeting, please submit a request on the conference website, contact your H.C. Wainwright or ...

TORONTO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory ...

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...